Empowering Reproductive Possibility
Next Biosciences is a leading South African biotech company which combines medicine, science and technology to invest in innovative health technologies with the core focus being to enable people to positively impact their health with science.
Next Biosciences offers a range of services that empower reproductive health decisions that matter most, and support you along your reproductive journey. One of these services include Preimplantation Genetic Testing for Aneuploidy (PGT-A), which is a genetic test that can be performed on embryos produced through IVF to screen for chromosomal abnormalities. The term ‘preimplantation’ is used because testing is performed on embryos during the time before they would naturally implant into the uterus (usually after day 6). PGT-A is offered as a complement to a patient’s in vitro fertilisation (IVF) treatment.
PGT-A offered by Next Biosciences aims to improve pregnancy success rates and reduce the risk of miscarriage by avoiding the transfer of embryos with the incorrect number of chromosomes
